BIOLASE (BLTI) Receives U.S. Patemt Entitled 'Methods for Treating Eye Conditions'
Tweet
Share
E-mailGet Alerts BLTI Hot Sheet
Join SI Premium – FREE
BIOLASE Technology, Inc. (Nasdaq: BLTI), announced that the U.S. Patent and Trademark Office has issued BIOLASE a new patent, number 7,997,279, titled "Methods for Treating Eye Conditions."
The new patent is the 13th patent issued in the ophthalmic patent family with 20 additional patents pending. It continues and expands patent number 7,665,467 with broad claims covering the use of laser technology for treating various conditions of the eye, including presbyopia, and opens up opportunities in oculoplastics, plus the treatment of glaucoma and cataracts.
The new patent is the 13th patent issued in the ophthalmic patent family with 20 additional patents pending. It continues and expands patent number 7,665,467 with broad claims covering the use of laser technology for treating various conditions of the eye, including presbyopia, and opens up opportunities in oculoplastics, plus the treatment of glaucoma and cataracts.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- Cleveland-Cliffs plans $1B upgrade at Middletown Works steel plant
- Walmart opens its 100th EV fast-charging site in Monument, CO
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
